Annual sales rose from KRW 158.1 billion in 2022 to KRW 160.6 billion in 2023, up 1.6%, then fell to KRW 128.5 billion in 2024, down 20.0%, and to KRW 113 billion in 2025, down 12.0%, marking two consecutive years of decline from 2024 to 2025.
Among the years from 2022 to 2025, 2023 was the largest and 2025 the smallest. The 2025 preliminary annual results announced on March 3, 2026 cited falling international grain prices and wider exchange-rate swings as the main drivers of the change in sales and earnings.
Operating losses of KRW 2.15 billion in 2022 and KRW 9.61 billion in 2023 gave way to operating profit of KRW 2.66 billion in 2024, a swing to profit. Operating profit rose 87.9% to KRW 4.99 billion in 2025, lifting the operating margin from -1.4% in 2022 and -6.0% in 2023 to 2.1% in 2024 and 4.4% in 2025.
Net losses attributable to controlling shareholders of KRW 282.8 billion in 2022 and KRW 217.7 billion in 2023 turned into net income of KRW 28.4 billion in 2024.
Net income attributable to controlling shareholders fell 84.6% to KRW 4.38 billion in 2025, so operating profit rose while net income fell, a pattern consistent with the large 2024 base. Whether any one-time items shaped the 2024 net income should be checked against the business report text.
Losses in 2022 and 2023 were reported to be driven largely by impairment losses on intangible assets tied to a bio business. Operating cash flow moved from -KRW 2.54 billion in 2022 and -KRW 7.91 billion in 2023 to KRW 860 million in 2024 and KRW 8.56 billion in 2025.
By quarter, the operating profit of KRW 1.7 billion in the fourth quarter of 2025 was the highest of the last five quarters, followed by KRW 370 million in the first quarter of 2026 and KRW 296 million in the second quarter, before an operating loss of KRW 204 million in the third quarter.
Third-quarter sales of KRW 29.9 billion were up 10.6% year on year, so volume grew while profitability weakened.
Net income attributable to controlling shareholders turned positive at KRW 433 million in the third quarter, diverging from the operating loss, which suggests non-operating items need to be considered alongside operating results. Net income attributable to controlling shareholders for the last four quarters totals KRW 2.25 billion.